Don't Hold Your Breath Waiting for a VIVUS Inc. Buyout
Last week, Aspen Investment disclosed a 9.65% stake in VIVUS and said it's considering a $640 million purchase, which would be made definitive by June 13.
As senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss in the following video, the key word there is "considering." By the size of its investment, it's clear Aspen thinks VIVUS is undervalued, but it's not clear whether the potential bid is a serious one or just a ploy to try to get the shares higher.
If it is a serious bid, it might not be the best news for Arena Pharmaceuticals and Orexigen , as it would put a floor on the potential price for obesity drugmakers. Arena Pharmaceuticals and Orexigen would be better off if VIVUS was being pursued by a large pharma, as it would give investors confidence that Arena and Orexigen might eventually be taken out by their respective partners, Eisai and Takeda.
Obesity drugmakers might be struggling, but our CIO likes this stock
Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Don't Hold Your Breath Waiting for a VIVUS Inc. Buyout originally appeared on Fool.com.Brian Orelli, David Williamson, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.